International
The Morning Science

What science found today

‹
 

Research

Spatial transcriptomics uncovers pharmacokinetic and tumor-intrinsic determinants of resistance to trastuzumab deruxtecan in breast cancer

Cell Reports Medicine · By Changhee Park, Minki Choi, Jiwon Koh, Sungwoo Bae, Hongyoon Choi, Kwon Joong Na, Yu-Jin Kim, Sujin Ham, Juyoun Lee, Yoonjung Shin, Dae-Won Lee, Kyung-Hun Lee, Han Suk Ryu, Tae-Yong Kim & Seock-Ah Im ·

The Brief

  • Park et al. performed spatial transcriptomics in patients with metastatic breast cancer treated with trastuzumab deruxtecan.
  • More spatially dispersed HER2 expression correlated with improved response.
  • In HER2-low tumors, resistant tumor fragments showed increased pharmacokinetic barriers.

Why it matters

The study points to spatial HER2 distribution and pharmacokinetic barriers as possible causes of resistance to a HER2-directed antibody-drug conjugate, which may inform patient selection and future drug design.

Who’s affected

  • oncologists and breast cancer researchers
  • clinicians treating metastatic HER2-low breast cancer

Park et al. perform spatial transcriptomics in patients with metastatic breast cancer treated with trastuzumab deruxtecan. More spatially dispersed HER2 expression correlates with improved response. In HER2-low tumors, resistant fragments show increased pharmacokinetic barriers…

Timeline

  1. Study on spatial transcriptomics and resistance to trastuzumab deruxtecan published in Cell Reports Medicine

  2. cell.com

    Spatial transcriptomics uncovers pharmacokinetic and tumor-intrinsic determinants of resistance to trastuzumab deruxtecan in breast cancer

How do you feel about this?

0 Comments

    Spatial transcriptomics uncovers pharmacokinetic and tumor-intrinsic determinants of resistance to trastuzumab deruxtecan in breast cancer – The Morning Science